There are more than a dozen ASX stocks focused on the respiratory space — from trying to tackle asthma
A * review of 13 small cap respiratory stocks has found that the majority are up year-on-year — led by one company that had a stellar 2018 financial year. Invion (ASX:IVX), which is testing a drug called INV104, is up a huge 1358 per cent over the past 12 months, going from 0.2c to 3.5c earlier today:
https://**promotion blocked**/wp-content/uploads/2018/08/Share-Price-41.jpg
Invion shares (ASX:IVX) over the past year
The drug works by blocking the actions of leukotrienes, preventing the increased mucus production, inflammation and narrowing of the airways that occurs in asthma.
IVX Price at posting:
3.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)